Alphaherpesvirus Vaccines
- PMID: 32963118
- PMCID: PMC8211365
- DOI: 10.21775/cimb.041.469
Alphaherpesvirus Vaccines
Abstract
Prophylactic and therapeutic vaccines for the alphaherpesviruses including varicella zoster virus (VZV) and herpes simplex virus types 1 and 2 have been the focus of enormous preclinical and clinical research. A live viral vaccine for prevention of chickenpox and a subunit therapeutic vaccine to prevent zoster are highly successful. In contrast, progress towards the development of effective prophylactic or therapeutic vaccines against HSV-1 and HSV-2 has met with limited success. This review provides an overview of the successes and failures, the different types of immune responses elicited by various vaccine modalities, and the need to reconsider the preclinical models and immune correlates of protection against HSV.
References
-
- Admedus, 2018. ADMEDUS HSV 2 PHASE IIA RESULTS - MAY 2017.
-
- Argaw T et al., 2000. Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. Journal of Infectious Diseases, 181(3), pp.1153–1157. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
